Pfizer Says Its COVID-19 Pill Reduces Death, Hospitalization Risk by 89%; Will Submit for FDA Approval Pfizer says that its COVID-19 pill reduced the risk of hospitalization or death by 89 percent in a clinical trial involving adults “at...

At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died Merck Plans to Seek Emergency Use Authorization...